CareSens S Clear BT Blood Glucose Monitoring System
K192859 · I-Sens, Inc. · NBW · Jan 24, 2020 · Clinical Chemistry
Device Facts
Record ID
K192859
Device Name
CareSens S Clear BT Blood Glucose Monitoring System
Applicant
I-Sens, Inc.
Product Code
NBW · Clinical Chemistry
Decision Date
Jan 24, 2020
Decision
SESE
Submission Type
Special
Regulation
21 CFR 862.1345
Device Class
Class 2
Attributes
Pediatric
Intended Use
The device system is intended for single-patient use only.
Device Story
CareSens S Clear BT Blood Glucose Monitoring System measures glucose in fresh capillary whole blood via test strips. Used by patients with diabetes at home for self-monitoring. Device consists of a meter and test strips; provides quantitative glucose results to aid diabetes management. Bluetooth connectivity enables data transmission. Single-patient use only.
Clinical Evidence
Bench testing only. Performance evaluated through accuracy and precision studies comparing system results to laboratory reference methods. Results demonstrate system meets established accuracy requirements for blood glucose monitoring systems.
Technological Characteristics
Electrochemical glucose measurement. Powered by two 3.0V CR2032 lithium batteries. Connectivity via Bluetooth and micro-USB. Features test strip ejector. Dimensions: 93.5 x 43.9 x 14.9 mm. Validated for cleaning/disinfection with Clorox Germicidal Wipes.
Indications for Use
Indicated for single-patient use for the quantitative measurement of glucose in capillary whole blood as a blood glucose monitoring system.
Regulatory Classification
Identification
A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.
Special Controls
*Classification.* Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
K193590 — CareSens S Fit BT Blood Glucose Monitoring System · I-Sens, Inc. · Jan 17, 2020
K201394 — CareSens N Feliz Blood Glucose Monitoring System, CareSens N Feliz BT Blood Glucose Monitoring System · I-Sens, Inc. · Oct 5, 2021
K182286 — Oh'Care Lite Smart Blood Glucose Monitoring System · Osang Healthcare Co. , Ltd. · Sep 19, 2018
K080283 — IDEAL LIFE GLUCO-MANAGER GMM 0001 BLOOD GLUCOSE MONITORING SYSTEM · Taidoc Technology Corporation · Jun 27, 2008
Submission Summary (Full Text)
{0}
FDA
U.S. FOOD & DRUG
ADMINISTRATION
# SPECIAL 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY
## I Background Information:
A 510(k) Number
K192859
B Applicant
i-SENS, Inc.
C Proprietary and Established Names
CareSens S Clear BT Blood Glucose Monitoring System
D Regulatory Information
| Product Code(s) | Classification | Regulation Section | Panel |
| --- | --- | --- | --- |
| NBW | Class II | 21 CFR 862.1345 - Glucose Test System | CH - Clinical Chemistry |
## II Review Summary:
This 510(k) submission contains information/data on modifications made to the submitter's own CLASS II device requiring 510(k). The following items are present and acceptable.
1. The name and 510(k) number of the SUBMITTER'S previously cleared device. The CareSens S Fit Blood Glucose Meter, k180866.
2. Submitter's statement that the INDICATIONS FOR USE/INTENDED USE of the modified device as described in its labeling HAS NOT CHANGED along with the proposed labeling which includes instructions for use, package labeling, and, if available, advertisements or promotional materials (labeling changes are permitted as long as they do not affect the intended use).
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
{1}
3. A description of the device MODIFICATION(S), including clearly labeled diagrams, engineering drawings, photographs, user's and/or service manuals in sufficient detail to demonstrate that the FUNDAMENTAL SCIENTIFIC TECHNOLOGY of the modified device has not changed. This change was for:
- Bluetooth connectivity was added to the meter.
- Data port was changed from a SMD type connector to a micro-USB port
- Dimensions of the meter were changed from 95 x 49 x 17.5 (mm) to 93.5 x 43.9 x 14.9 (mm)
- Meter was changed to add a test strip ejector
- Power source was changed from one 3.0 V lithium battery (CR2032) to two 3.0 V lithium battery (CR2032)
- Change in name from CareSens S Fit Blood Glucose Monitoring System to CareSens S Clear BT Blood Glucose Monitoring System.
4. Comparison Information (i.e., similarities and differences) to the submitter's legally marketed predicate device including, labeling, intended use, and physical characteristics.
5. A Design Control Activities Summary which includes:
a) Identification of Risk Analysis method(s) used to assess the impact of the modification on the device and its components, and the results of the analysis.
b) Based on the Risk Analysis, an identification of the verification and/or validation activities required, including methods or tests used and acceptance criteria to be applied.
The labeling for this modified subject device has been reviewed to verify that the indication/intended use for the device is unaffected by the modification. In addition, the submitter's description of the particular modification(s) and the comparative information between the modified and unmodified devices demonstrate that the fundamental scientific technology has not changed. The submitter has provided the design control information as specified in The New 510(k) Paradigm and on this basis, I recommend the device be determined substantially equivalent to the previously cleared (or their preamendment) device.
The device system is intended for single-patient use only. Disinfection efficacy studies were performed on the external meter materials by an outside commercial testing laboratory demonstrating complete inactivation of hepatitis B virus (HBV) with Clorox Germicidal Wipes (EPA Reg. No: 67619-12). The sponsor also conducted robustness studies demonstrating that there was no change in performance or in the external materials of the meter after 260 cleaning and disinfection cycles using the chosen wipe representing 5 years of single patient use. Labeling was reviewed for adequate instructions for the validated cleaning and disinfection procedures.
K192859 - Page 2 of 2
Panel 1
/
Sort by
Ready
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.
Sort by:
Create Alert
Search Filters
Agent Token
Create a read-only bearer token for Claude, ChatGPT, or other agents that can call HTTP APIs.